Widespread hypertranscription in aggressive human cancers

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Cancers are characterized by transcriptional dysregulation, but global changes are poorly understood.
• Hypertranscription (genome-wide RNA output increase) prevalence and significance in primary human cancers remain undefined.
• Existing expression profiling methods have limitations in accurately measuring global RNA output differences.

Purpose of the Study:

• To develop and apply a computational method for directly measuring hypertranscription in human cancers.
• To investigate the prevalence, drivers, and prognostic significance of hypertranscription across diverse cancer types.
• To explore the role of hypertranscription in cancer progression and response to therapy.

Main Methods:

• Development of a novel computational method to quantify hypertranscription from existing tumor expression data.
• Analysis of a large dataset of 7494 human tumors across 31 cancer types.
• Integration of single-cell analysis to identify hypertranscribing clones and their contribution to RNA production.

Main Results:

• Hypertranscription is a ubiquitous phenomenon in human cancers, particularly prevalent in aggressive forms.
• Hypertranscription identifies patient subgroups with significantly worse survival outcomes, even within specific cancer subtypes.
• Loss of transcriptional suppression appears to be a key driver of the hypertranscriptional phenotype.
• Single-cell analysis revealed that hypertranscribing clones disproportionately contribute to overall RNA output.
• Patients with hypertranscribed mutations showed an enhanced response to immune checkpoint therapy.

Conclusions:

• Hypertranscription is a fundamental aspect of gene dysregulation across human cancers with significant prognostic implications.
• The developed computational method enables direct measurement of hypertranscription, overcoming limitations of previous techniques.
• Understanding hypertranscription offers new insights into cancer biology and may guide the identification of patients suitable for novel therapeutic strategies, including immune checkpoint inhibitors.